Skip to content
January 27, 2020

aiForward project assessing PD-L1 in lung cancer nears completion

“When I first started, I did not know anything about AI,” describes Liesbeth Hondelink, MSc student at Leiden University Medical Centre in the Netherlands, when she applied to the aiForward program.
Her research focuses on PD-L1, a protein which has gained much popularity in a field that has been under the spotlight for some time now: cancer immunotherapy. Liesbeth and her lab are specifically assessing the programmed death-ligand 1 in non-small cell lung cancer (NSCLC).
Read the rest on the aiForward website.